NCT02003677已完成1 期
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- Area under the glucose infusion rate curve
研究概览
简要总结
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body)properties of FIAsp (faster-acting insulin aspart) in geriatric and younger adult subjects with type 1 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18-35 years (both inclusive) (younger adult group) or below or equal to 65 years (geriatric group) at the time of signing informed consent
- •Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
- •Body mass index (BMI) 18.5-28.0 kg/m^2 (both inclusive)
排除标准
- •Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
- •Smoker (defined as a subject who is smoking at least one cigarette, cigar or pipe daily)
- •Not able or willing to refrain from smoking and use of nicotine substitute products during the inpatient period
研究组 & 干预措施
FIAsp followed by NovoRapid®
Experimental
Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
干预措施: Faster-acting insulin aspart (Drug)
NovoRapid® followed by Insulin aspart
Active Comparator
Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
干预措施: insulin aspart (Drug)
结局指标
主要结局
Area under the glucose infusion rate curve
时间窗: From 0 to 12 hours
次要结局
- Area under the serum insulin aspart concentration-time curve(From 0 to 12 hours)
- Maximum observed serum insulin aspart concentration(From 0 to 12 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01924637Novo Nordisk A/S36
已完成
1 期
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy SubjectsHealthyDiabetesNCT01931137Novo Nordisk A/S45
已完成
1 期
A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT02035371Novo Nordisk A/S41
已完成
1 期
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT01773798Novo Nordisk A/S33
已完成
1 期
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentHealthyDiabetesDiabetes Mellitus, Type 2NCT02016911Novo Nordisk A/S56